Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its target price lifted by equities research analysts at Barclays from $271.00 to $275.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Barclays‘s target price would indicate a potential upside of 19.40% from the company’s previous close.
Several other equities research analysts have also weighed in on the company. Morgan Stanley cut their target price on Jazz Pharmaceuticals from $322.00 to $314.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 21st. Stifel Nicolaus set a $275.00 price target on Jazz Pharmaceuticals in a report on Tuesday, August 4th. Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an “outperform” rating in a research note on Tuesday. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $337.00 price objective on the stock. Finally, Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $292.70.
Check Out Our Latest Stock Analysis on JAZZ
Jazz Pharmaceuticals Stock Up 7.4%
NASDAQ:JAZZ traded up $15.88 during trading hours on Tuesday, hitting $230.32. The company’s stock had a trading volume of 215,950 shares, compared to its average volume of 927,309. The stock has a market capitalization of $14.95 billion, a P/E ratio of 15.70, a price-to-earnings-growth ratio of 0.41 and a beta of 0.38. The stock has a fifty day moving average of $231.16 and a 200-day moving average of $216.50. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a 52-week low of $128.80 and a 52-week high of $266.38.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.05) by $0.17. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. Jazz Pharmaceuticals’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm earned $8.13 earnings per share. On average, equities analysts forecast that Jazz Pharmaceuticals will post 10.87 earnings per share for the current year.
Insider Transactions at Jazz Pharmaceuticals
In related news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the sale, the executive vice president owned 47,671 shares in the company, valued at $11,485,850.74. This represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the transaction, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. The trade was a 53.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 94,121 shares of company stock worth $23,337,922. 4.10% of the stock is currently owned by corporate insiders.
Institutional Trading of Jazz Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in the stock. USA Financial Formulas purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at $25,000. Pension & Wealth Management Advisors Inc. acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $32,000. Ameritas Advisory Services LLC purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $47,000. Westpac Banking Corp purchased a new position in Jazz Pharmaceuticals during the 1st quarter worth $51,000. Finally, Root Financial Partners LLC raised its position in Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after buying an additional 89 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.
Key Jazz Pharmaceuticals News
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz reported third-quarter revenue of approximately $1.24 billion, up 10.4% year over year and above the roughly $1.21 billion analyst estimate. Adjusted loss of $3.88 per share was narrower than the consensus loss of $4.05. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
- Positive Sentiment: The company raised its fiscal 2026 revenue outlook to approximately $4.8 billion-$4.9 billion, above the $4.7 billion-$4.73 billion consensus range. The increased forecast signals continued confidence in commercial execution. Jazz 2026 Revenue Guidance
- Positive Sentiment: Ziihera launched in first-line HER2-positive metastatic gastric and esophageal cancer, while management identified potential peak sales of $3 billion-$5 billion. Xywav revenue also grew 12%, with 425 net patient additions during the quarter. Ziihera Launch and Guidance
- Neutral Sentiment: Jazz completed its Actio acquisition, adding the ABS-1230 epilepsy candidate to its rare-neurology portfolio. The company will also present Phase 3 ACTION and Phase 2 brain-cancer research at the Society for Neuro-Oncology meeting, offering potential future catalysts but no immediate revenue impact. Jazz Neuro-Oncology Research
- Negative Sentiment: The quarter’s loss contrasts sharply with $8.13 per-share earnings a year earlier. Investors may also remain cautious about decelerating growth and acquisition-related charges associated with Actio, leaving the stock at a crossroads despite the improved outlook. Jazz Earnings and Guidance Analysis
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Articles
- Five stocks we like better than Jazz Pharmaceuticals
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
- Check Point’s Turnaround Could Be Closer Than Investors Think
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
